Modeling Molecular Pathogenesis of Idiopathic Pulmonary Fibrosis-Associated Lung Cancer in Mice
I. Barravecchia, J. M. Lee, J. Manassa, B. Magnuson, S. Cavanaugh, N. G. Steele, C. Espinoza, C. J. Galban, N. Ramnath, T. L. Frankel, M. Pasca di Magliano, S. Galban
Abstract
Idiopathic Pulmonary Fibrosis (IPF) is characterized by progressive, often fatal loss of lung function due to overactive collagen production and tissue scarring. IPF patients have a sevenfold-increased risk of developing lung cancer. The COVID-19 pandemic has increased the number of patients with lung diseases, and infection can worsen prognoses for those with chronic lung diseases and disease-associated cancer. Understanding the molecular pathogenesis of IPF-associated lung cancer is imperative for identifying diagnostic biomarkers and targeted therapies that will facilitate prevention of IPF and progression to lung cancer. To understand how IPF-associated fibroblast activation, matrix remodeling, epithelial-mesenchymal transition, and immune modulation influences lung cancer predisposition, we developed a mouse model to recapitulate the molecular pathogenesis of pulmonary fibrosis-associated lung cancer using the bleomycin and the Lewis Lung Carcinoma models. Models of pulmonary fibrosis, particularly bleomycin-induced fibrosis, do not recapitulate all aspects of human disease; however, to simplify nomenclature, we refer to our bleomycin-induced fibrosis model as IPF. We demonstrate that development of pulmonary fibrosis-associated lung cancer is linked to increased recruitment or reprogramming of tumor-associated macrophages and a unique gene signature that supports an immune-suppressive microenvironment through secreted factors. Not surprisingly, pre-existing fibrosis provides a pre-metastatic niche and results in augmented tumor growth. Tumors associated with bleomycin-induced fibrosis are characterized by an epithelial-to-mesenchymal transition characterized by dramatic loss of cytokeratin expression. ImplicationsWe provide new therapeutic targets that may aid the characterization of tumors associated with lung diseases and development of treatment paradigms for lung cancer patients with pre-existing pulmonary diseases.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Ferret model of bleomycin-induced lung injury shares features of human idiopathic pulmonary fibrosis
Shuang Wu, Ian Driver, … Xiaoming Liu·npj Regenerative MedicinePeer-reviewed·Nov 21, 2025
- Loss of Fas-signaling in pro-fibrotic fibroblasts impairs homeostatic fibrosis resolution and promotes persistent pulmonary fibrosis
E. F. Redente, S. Chakraborty, … D. W. H. Riches·bioRxiv·Aug 18, 2020
- Connective-Tissue Growth Factor (CTGF/CCN2) Contributes to TGF-β1-Induced Lung Fibrosis
T. Yanagihara, S. G. Chong, … M. R. Kolb·bioRxiv·Jul 4, 2020
- Wilms tumor 1 impairs apoptotic clearance of fibroblasts in distal fibrotic lung lesions
Harshavardhana H. Ediga, Chanukya P. Vemulapalli, … Satish Kumar Madala·Journal of Clinical InvestigationPeer-reviewed·Jun 10, 2025
- Engineering a 3D Lung Co-culture Platform to Model Epithelial-Fibroblast Interactions in Pulmonary Fibrosis
Mejalaa Mega Jayaseelan, Aleksander Skardal, … Megan N. Ballinger·bioRxiv·May 13, 2026
- A Simultaneous Inhibition of ID1 and ID3 Protects Against Pulmonary Fibrosis
Samar A. Antar, Eric Mensah, … Yassine Sassi·bioRxiv·Jul 24, 2025